Clinical Trial

Prospective Breast Cancer Biobanking

Study acronym: PBCB
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated July 30, 2020 (before its estimated July 15, 2022 completion). Its status may not reflect the trial's current state.
Summary
Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A. Early detection of systemic relapses B.Improve adherence and drug monitoring av tamoxifen treatment C. Tumour microenvironment in breast cancer - adipose stromal immune infiltration and interaction with tumour at the growth zone D.Monitor side effects, QoL, depression, fatigue and work life participation
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-07-25.
Trial Details
NCT Number NCT04488614
Lead Sponsor Helse Stavanger HF
Collaborators: Helse-Bergen HF
Conditions Breast Cancer
Enrollment 1,200 participants
Start Date 2011-09-01
Primary Completion 2022-07-15 (estimated)
Study Completion 2030-07-15 (estimated)
Updated on ClinicalTrials.gov 2020-07-30